Abbisko Cayman Limited (2256.HK) HKSE
9.24
-0.28(-2.94%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
9.24
-0.28(-2.94%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
281
First IPO Date
October 13, 2021
| Name | Title | Pay | Year Born |
| Yao-Chang Xu | Founder, Chairman of the Board & Chief Executive Officer | 5.07M | 1957 |
| Hongping Yu | Co-Founder, SVP of Chemistry, Chief Scientific Officer & Executive Director | 3.43M | 1968 |
| Jing Ji | Chief Medical Officer & Executive Director | 5.78M | 1970 |
| Zhen Zhang | Senior VP of CMC & Head of Chemistry, Manufacturing and Controls | 0 | 1973 |
| Zidong Zhang | Group Chief Financial Officer | 0 | 1981 |
| Yongyi Li | General Counsel | 0 | 1976 |
| Hanxi Zhang | Joint Company Secretary | 0 | N/A |
| Sio Ngo Lin | Joint Company Secretary | 0 | N/A |
| Jia Feng | Vice President of HR and Operations & Head of Human Resource | 0 | N/A |
| Yin Wah Chan FCCA FCIS HKICS | Joint Company Secretary | 0 | 1975 |
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.